A new drug for pancreatic cancer - daraxanrasib, sold under the brand name "Rasonque," has been approved by the FDA and has shown that patients taking this drug lived an average of 13.2 months, compared to 6.6 months with chemotherapy, providing a new opportunity to treat one of the deadliest forms of cancer. (translated)












